Our Services
Services We Provide
Proteins are major building blocks of the body, and an individual’s DNA is the “instruction manual” used to produce about 20K distinct proteins, each encoded by a unique gene. If abnormalities occur in certain genes, disease can develop as a result of the irregular protein.
Intellimedix aims to support clients in both a clinical setting and pharmaceutical R&D by identifying and analyzing disease causing mutations in the human genome. Our suite of algorithms have been developed by the Chief Scientific Officer (CSO) of Intellimedix over the last 10 years and are optimized to accelerate the process of diagnosing diseases and identifying novel treatments.
Clinical
Intellimedix provides a personalized approach from diagnosis to treatment. By working with your physician, our services will provide novel insights to the cause of a disease and alternative treatment options – giving you the best care possible.
Pharmaceutical Research and Development
Finding new targets and drugs can be both time consuming and costly. By using Intellimedixes proprietary software, our team will assist in finding new drug targets, targeted treatments, or repurposing your existing portfolio of small molecules – maximizing results while minimizing time and cost.
Pharmaceutical Research and Development
For every 10,000 potential drugs researched by pharmaceutical companies, only one will make it to market with an estimated cost to produce of over $1 billion. This process takes on average 15 years, which leaves the pharmaceutical company 5 years of exclusivity in the US on the 20-year patent before generics of the compound will come to market.
Intellimedix utilizes a set of algorithms and associated platforms to accelerate pharmaceutical R&D. Our diverse set of tools minimize CPU time and false positives, giving our partners the ability to accurately identify new leads for biomarkers, protein targets, and drugs. The core algorithms combine the power of big data analysis with mutation characterization and protein modeling to produce two key results: Mutations that are likely to cause a given disease and small molecules that are likely to bind to a given protein target. The results – a more accurate and efficient methodology to discover biomarkers and repurpose existing drugs.
